Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists

Telo Genomics (TELO.V) said the College of American Pathologists (CAP) will add the company's test for smoldering multiple myeloma (SMM), TeloViewSMM, as a Laboratory Developed Test (LDT) on CAP's app

MT NewswiresJun 18 09:21 ET

Telo Genomics Receives Accreditation From College of American Pathologists

Telo Genomics (TELO.V) a biotech company developing a telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, on Wednesday said the Accredit

MT NewswiresApr 10 13:21 ET

Telo Genomics' MRD Clinical Trial Expands Into Multi-Center Trial; Shares up 9.5%

Telo Genomics (TELO.V) a biotech company developing a telomere technology platform with applications measuring genomic instability in oncology, reports that patient recruitment for its minimal residua

MT NewswiresApr 2 13:42 ET